New drug delays progression of glioma, a deadly brain cancer

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor. The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news